Param Hari

Transplant and Myeloma Physician in Milwaukee

[Param Hari @Docmyeloma]

@Rfonsi1 @Phari

[Talha Badar @TalhaBadarMD]

Nice time with fellows and colleagues from MCW! # ASH 2017

[MPN Research Foundation @MPN_RF]

Congratulations to Dr. Vikas Gupta and all the other @cure_magazine MPN Heroes! Vikas is pictured here with nominator & MPN caregiver Cheryl Petruk of the Canadian MPN Research Foundation & MPNRF. #ASH17 #MPNSM #MPNHeroes17

[Aaron Logan, MD, PhD, MPhil @hemedoc]

#ASH17 #leusm Modvig: flow cytometry and PCR-based MRD quantification correlate well. 10% of T-ALL did not have a clonal TCR for molecular MRD quantification.

[Param Hari @Docmyeloma]

Dr. Chhabra presents CML allo transplant data at #ASH17 @MediHumdani

[Nina Shah @ninashah33]

EMN02: better PFS and OS with tandem ASCT and maybe benefits high risk pts the most. How to reconcile with BMTCTN 0702? #MYELOMA

[Param Hari @Docmyeloma]

@akeithstewart Eradicate MM; if double high dose Mel increases OS ; something better for OS needed before transplant eradicated

[CIBMTR @CIBMTR]

CIBMTR investigators presenting during the 7:00 – 8:30 a.m. oral session in Building B, Level 3, B312-B314 #ASH17 https://t.co/jL9auI3JcQ

[Julie Vose @DrJulieVose]

Very impressive responses with the BCMA directed CAR-T. It would be great to have more sites open for enrollment for these difficult to treat patients. https://t.co/V3Kyhcwo9j

[Raul Cordoba, MD, PhD @DrRaulCordoba]

Age barriers to alloHSCT #geriheme #bmtsm #ASH17 https://t.co/fZ2Iu9ThY5

[Param Hari @Docmyeloma]

Waaay too harsh - what's next denying care to older folk because they're addicted to living? https://t.co/0nzrMMgr1d

[Philip McCarthy @PLMcCarthyMD]

This is a bit harsh. NHS provokes fury with indefinite surgery ban for smokers and obese ' | via @telegraph https://t.co/7UdgRrBBuo

[Jeff Szer @marrow]

Current clinical trials in myeloma as presented by Simon Harrison #cuttingedgehaem @VicCompCancerCr @WEHI_research

[Mehdi Hamadani, MD @MediHumdani]

Higher infection risk w/ severe CRS in CAR-T. Poss due to Tociluzumab as seen with Toci use in GVHD? #lymsm #bmtsm
https://t.co/qZ2vLdimvi

[Mehdi Hamadani, MD @MediHumdani]

.@CIBMTR Score for #MDS underoing allogeneic HCT by @wlsaber #bmtsm (PB blast%, plt<50, age, Cyto, KPS prognostic) https://t.co/j8zkEX1PGr

[Param Hari @Docmyeloma]

May threaten financial viability of BMT programs if this is true https://t.co/OozeCO2DfA

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

Great addition x BMT pts ! It's not fair to the BMT prog! Medicare paid $ 64k allo & 34 K Auto - 1 drug cost $ 156k https://t.co/NQ5mGkai7V

[Mehdi Hamadani, MD @MediHumdani]

PhaseII Bu/CY/VP-16 for autoHCT in #Lymphoma. @CIBMTR Another trial to show conditionings won't improve HCT outcomes https://t.co/7EtPOcEjAF

[Sofia @Chris_tinees]

Trevor Noah burns Kasich for saying Trump is lucky Jon Stewart isn't around https://t.co/usS7yvdg3j

[Mehdi Hamadani, MD @MediHumdani]

Posttransplant bendamustine reduces GvHD while preserving GvL in experi.... https://t.co/UcKG2S9y5F https://t.co/ehITqhvFzE

[Vincent Rajkumar @VincentRK]

An important guideline from the #IMWG - More to follow. We meet in June at Copenhagen @IMFmyeloma @MyelomaTeacher https://t.co/u80kn4PPf1